Literature DB >> 16898638

Easier node dissection after chemoradiotherapy for lung cancer with collagen insertion at mediastinoscopy.

Kenichi Okubo1, Masashi Kobayashi, Hiromasa Morikawa, Eiichi Hayatsu.   

Abstract

OBJECTIVE: Induction chemoradiotherapy followed by anatomical resection is a current therapeutic strategy for non-small-cell lung cancer with mediastinal node involvement. Dense peritracheal fibrosis and sclerosis after chemoradiotherapy cause difficult mediastinal node dissection. We evaluated a novel technique to make the mediastinal node dissection easier after induction therapy.
METHODS: At the end of mediastinoscopic node biopsy for staging of lung cancer, cotton-type collagen was inserted anterior and lateral to the trachea in patients with pathologically confirmed mediastinal node involvement (n=45). The induction therapy consisted of concurrent use of platinum-based chemotherapy and hyperfractionated radiotherapy. After the chemoradiotherapy all patients underwent a pulmonary resection with complete mediastinal node dissection 7-12 weeks after the collagen insertion. Surgical findings of the mediastinum and the time for node dissection were compared with those without collagen insertion at mediastinoscopy after chemoradiotherapy (n=5).
RESULTS: All five patients without collagen insertion showed sclerotic and fibrotic change of mediastinal nodes with severe adhesion to the trachea. In 42 of 45 patients with collagen insertion (93.3%) the collagen remained unabsorbed and separated the mediastinal nodes from the trachea. Mediastinal node dissection was easily accomplished by removing mediastinal tissues lateral and anterior to the collagen. The rate of mediastinal node separation was significantly higher with collagen insertion than without (p<0.0001). The times for node dissection in patients with and without collagen insertion showed no significant difference.
CONCLUSION: Cotton-type collagen insertion at staging mediastinoscopy for lung cancer separates the mediastinal nodes from the trachea and makes the node dissection easier after induction chemoradiotherapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16898638     DOI: 10.1007/pl00022251

Source DB:  PubMed          Journal:  Jpn J Thorac Cardiovasc Surg        ISSN: 1344-4964


  10 in total

1.  A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group.

Authors:  S M Keller; S Adak; H Wagner; A Herskovic; R Komaki; B J Brooks; M C Perry; R B Livingston; D H Johnson
Journal:  N Engl J Med       Date:  2000-10-26       Impact factor: 91.245

2.  Cotton-type collagen insertion at mediastinoscopy for easier node dissection after induction chemoradiotherapy for lung cancer.

Authors:  Kenichi Okubo; Jun Isobe; Toshihiko Sato; Yoichiro Ueno
Journal:  J Thorac Cardiovasc Surg       Date:  2004-05       Impact factor: 5.209

3.  [Evaluation of blood absorption, hemostatic ability and purity of a polyepoxy compound cross-linked cotton type collagen hemostat].

Authors:  Y Tomizawa; Y Noishiki; M Endo; A Hashimoto; H Koyanagi
Journal:  Kyobu Geka       Date:  1996-02

4.  Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial.

Authors:  W Eberhardt; H Wilke; G Stamatis; M Stuschke; A Harstrick; H Menker; B Krause; M R Müeller; M Stahl; M Flasshove; V Budach; D Greschuchna; N Konietzko; H Sack; S Seeber
Journal:  J Clin Oncol       Date:  1998-02       Impact factor: 44.544

5.  The biological operability of stage III non-small cell lung cancer.

Authors:  C F Mountain
Journal:  Ann Thorac Surg       Date:  1985-07       Impact factor: 4.330

6.  Value of accelerated multimodality therapy in stage IIIA and IIIB non-small cell lung cancer.

Authors:  Malcolm M DeCamp; Thomas W Rice; David J Adelstein; Mark A Chidel; Lisa A Rybicki; Sudish C Murthy; Eugene H Blackstone
Journal:  J Thorac Cardiovasc Surg       Date:  2003-07       Impact factor: 5.209

7.  A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.

Authors:  R Rosell; J Gómez-Codina; C Camps; J Maestre; J Padille; A Cantó; J L Mate; S Li; J Roig; A Olazábal
Journal:  N Engl J Med       Date:  1994-01-20       Impact factor: 91.245

8.  Assessment of preoperative accelerated radiotherapy and chemotherapy in stage IIIA (N2) non-small-cell lung cancer.

Authors:  D J Mathisen; J C Wain; C Wright; N Choi; R Carey; A Hilgenberg; M Grossbard; T Lynch; H Grillo
Journal:  J Thorac Cardiovasc Surg       Date:  1996-01       Impact factor: 5.209

9.  Adjuvant chemotherapy for completely resected stage III non-small-cell lung cancer. Results of a randomized prospective study. The Japan Clinical Oncology Group.

Authors:  M Ohta; R Tsuchiya; M Shimoyama; K Sawamura; T Mori; N Miyazawa; K Suemasu; Y Watanabe; M Tomita; M Terashima
Journal:  J Thorac Cardiovasc Surg       Date:  1993-10       Impact factor: 5.209

10.  Randomized trial of neoadjuvant therapy for lung cancer: interim analysis.

Authors:  H I Pass; H W Pogrebniak; S M Steinberg; J Mulshine; J Minna
Journal:  Ann Thorac Surg       Date:  1992-06       Impact factor: 4.330

  10 in total
  1 in total

1.  Hyperfractionated irradiation with 3 cycles of induction chemotherapy in stage IIIA-N2 lung cancer.

Authors:  Fengshi Chen; Kenichi Okubo; Makoto Sonobe; Keiko Shibuya; Yukinori Matsuo; Young Hak Kim; Kazuhiro Yanagihara; Toru Bando; Hiroshi Date
Journal:  World J Surg       Date:  2012-12       Impact factor: 3.352

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.